Genetic basis for idiosyncratic reactions to antiepileptic drugs

Current Opinion in Neurology

Volumn 22, Issue 2, 2009, Pages 144-149

  Franciotta, Diego ^a   Kwan, Patrick ^b   Perucca, Emilio ^a,c  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Antiepileptic drugs; Human leukocyte antigens; Idiosyncratic reactions; Pharmacogenomics; Review

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GLUTATHIONE TRANSFERASE; HLA B ANTIGEN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID; VIGABATRIN; TERATOGENIC AGENT;

ADVERSE DRUG REACTION; ALLELE; ANTICONVULSANT THERAPY; ASIAN; CLINICAL RESEARCH; DRESS SYNDROME; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; EPILEPSY; ETHNIC DIFFERENCE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC LINKAGE; GENETIC RISK; GENETIC SUSCEPTIBILITY; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; MACULOPAPULAR RASH; PATIENT IDENTIFICATION; PHARMACOGENETICS; PHARMACOGENOMICS; REVIEW; RISK ASSESSMENT; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TERATOGENICITY; TOXIC EPIDERMAL NECROLYSIS; TOXICOGENETICS; VISUAL FIELD DEFECT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GENETICS; IMMUNOLOGY; LIVER DISEASE; VISUAL FIELD;

ANTICONVULSANTS; CARBAMAZEPINE; DRUG HYPERSENSITIVITY; EPILEPSY; GLUTATHIONE TRANSFERASE; HLA-B ANTIGENS; HUMANS; LIVER DISEASES; STEVENS-JOHNSON SYNDROME; TERATOGENS; VALPROIC ACID; VIGABATRIN; VISUAL FIELDS;

EID: 68849092410     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328328f276     Document Type: Review

References (44)

1. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007; 48:1223-1244.
2. EdwardsSG,HubbardV,AylettS,WrenD.Concordanceofprimarygeneral-ised epilepsy and carbamazepine hypersensitivity in monozygotic twins. Postgrad Med 1999; 75:680-681.
3. Pirmohamed M, Lin K, Chadwick D, Park K. TNF-a promoter region gene polymorphisms in carbamazepine hypersensitive patients. Neurology 2001; 56:890-896.
4. Alfirevic A, Mills T, Harrington P, et al. Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet Genomics 2006; 16:287-296.
5. ChungWH,HungSI,HongHS, et al. Medicalgenetics:amarkerforStevens-Johnson syndrome. Nature 2004; 428:486.
6. HungSI,ChungWH,JeeSH, et al. Geneticsusceptibilitytocarbamazepine inducedcutaneousadversedrugreactions.PharmacogenetGenomics2006; 16:297-306.
7. Man CB, Kwan P, Baum L, et al. Association between HLA-B 1502 allele andantiepilepticdrug-inducedcutaneousreactionsinHanChinese.Epilepsia 2007; 48:1015-1018.
8. LocharernkulC, Loplumlert J,Limotai C, et al. Carbamazepine andphenytoin inducedStevens-Johnsonsyndromeisassociatedwith HLA-B 1502 allelein Thai population. Epilepsia 2008; 49:2087-2091.
9. Alfirevic A, Jorgensen AL, Williamson PR, et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006; 7:813-818.
10. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome . . .: ethnicity matters. Pharmacogenomics J 2006; 6:265-268.
11. LonjouC,BorotaN,SekulaeP, et al. AEuropeanstudyofHLA-BinStevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18:99-107.
12. Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with antiepileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9:1617-1622.
13. Chung WH, Hung SI, Chen YT. Human leukocytes antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007; 7:317-323.
14. Pirmohamed M, Arbuckle JB, Bowman CE, et al. Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2007; 8:1661-1691.
15. U.S. Food and DrugAdministration. InformationforHealthcare Professionals Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics). http://www.fda.gov/cder/drug/InfoSheets/HCP/carbamazepineHCP.htm. [Accessed December 12, 2008]
16. Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharma-cogeneticsonthetreatmentofepilepsy.Epilepsia2008[Epubaheadofprint].
17. Hoa BK, Hang NT, Kashiwase K, et al. HLA-A, -B, -C, -DRB1 and -DQB1 alleles and haplotypes in the Kinh population in Vietnam. Tissue Antigens 2008; 71:127-134.
18. Tang TF, Hou L, Chen M, et al. HLA haplotypes in Singapore: a study of mothers and their cord blood units. Human Immunol 2007; 68:430-438.
19. Lim KS, Kwan P, Tan CT. Association of HLA-B 1502 allele and carbama-zepine-induced severe adverse cutaneous drug reaction among Asians, a review. Neurology Asia 2008; 13:15-21.
20. Solberg OD, Mack SJ, Lancaster AK, et al. Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies. Human Immunol 2008; 69:443-464.
21. FerrellPBJr,McLeodHL.Carbamazepine,HLA-B 1502andriskofStevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008; 9:1543-1546.
22. Hung S-I, Chung W-H, Chen Y-T. HLA-B genotyping to detect carbamaze-pine-inducedStevens-Johnsonsyndrome:implicationsforpersonalizingmed- icine. Personalized Med 2005; 2:225-237.
23. Chen Y-C, Chu C-Y, Hsiao C-H. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype. J Eur Acad Dermat Venereol 2008 [Epub ahead of print]. doi: 10.1111/j.1468-3083.2008.02988.x.
24. U.S. Food and Drug Administration.Phenytoinand fosphenytoin information. FDA Alter 24 Nov 2008. http://www.fda.gov/CDER/drug/infopage/pheny-toin- fosphenytoin/default.htm. [Accessed December 15, 2008]
25. UedaK,IshitsuT,SeoT, et al. Glutathione S-transferase M1 nullgenotypeas a risk factor for carbamazepine-induced mild hepatotoxicity. Pharmacoge-nomics 2007; 8:435-442.
26. FukushimaY,SeoT,HashimotoN, et al. Glutathione S-transferase (GST) M1 null genotype and combined GSTM1 and GSTT1 null genotypes are risk factors for increased serum g-glutamyltransferase in valproic acid-treated patients. Clin Chim Acta 2008; 389:98-102.
27. König SA, Siemes H, Bläker F, et al. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 1994; 35:1005-1015.
28. SilvaMF,AiresCC,LuisPB, et al. Valproicacidmetabolismanditseffectson mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 2008 [Epub ahead of print].
29. Horvath R, Hudson G, Ferrari G, et al. Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. Brain 2006; 129:1674-1684.
30. Tzoulis C, Engelsen BA, Telstad W, et al. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain 2006; 129:1685-1692.
31. McFarlandR,HudsonG,TaylorRW, et al. Reversiblevalproatehepatotoxicity due to mutations in mitochondrial DNA polymerase gamma (POLG1). Arch Dis Child 2008; 93:151-153.
32. Lin CM, Thajeb P. Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA. Metab Brain Dis 2007; 22:105-109.
33. Galimberti CA, Diegoli M, Sartori I, et al. Brain pseudoatrophy and mental regressiononvalproateandamitochondrialDNAmutation.Neurology2006; 67:1715-1717.
34. Williams DC Jr, Massey GV, Russell EC, et al. Translocation-positive acute myeloidleukemiaassociatedwithvalproicacidtherapy.PediatrBloodCancer 2008; 50:641-643.
35. Wild JM, Ahn HS, Baulac M, et al. Vigabatrin and epilepsy: lessons learned. Epilepsia 2007; 48:1318-1327.
36. Kinirons P, Cavalleri GL, Singh R, et al. A pharmacogenetic exploration of vigabatrin-inducedvisualfieldconstriction.EpilepsyRes2006;70:144-152.
37. Sankar R. Teratogenicity of antiepileptic drugs: role of drug metabolism and pharmacogenomics. Acta Neurol Scand 2007; 116:65-71.
38. BuehlerBA,DelimontD,vanWaesM,FinnellRH.Prenatalpredictionofriskof the fetal hydantoin syndrome. N Engl J Med 1990; 322:1567-1572.
39. AtkinsonDE,SophieBrice-BennettS,D'SouzaSW.Antiepilepticmedication during pregnancy: does fetal genotype affect outcome? Pediatr Res 2007; 62:120-127.
40. BottoLD,YangQ.5,10-Methylenetetrahydrofolatereductasegenevariantsand congenital anomalies: a HuGE review. Am J Epidemiol 2000; 151:862-877.
41. Dean JC, Moore SJ, Osborne A, et al. Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene. Clin Genet 1999; 56:216-220.
42. Dean J, Robertson Z, Reid V, et al. Fetal anticonvulsant syndromes and polymorphisms in MTHFR, MTR, and MTRR. Am J Med Genet A 2007; 143A:2303-2311.
43. DeanJC,RobertsonZ,ReidV, et al. AhighfrequencyoftheMTHFR677C>T polymorphisminScottishwomenwithepilepsy:possibleroleinpathogenesis. Seizure 2008; 17:269-275.
44. KiniU, LeeR,JonesA, et al. Influence ofthe MTHFR genotypeontherate of malformations following exposure to antiepileptic drugs in utero. Eur J Med Genet 2007; 50:411-420.